The medical industry hit the Internet, just like picking up a magnifying glass, at least in terms of drug traceability data, magnified the problems in the public. In the "Measures for the Supervision and Administration of Drug Network Sales" promulgated in the first half of this year, this issue has once again attracted attention. In the "Measures", it is emphasized that it is forbidden to sell prescription drugs to individual consumers and prohibit the sale of drugs by single pharmacies. In addition, the prescription drug display function of the medical e-commerce platform is also prohibited.
However, all of this will appear to be the most stringent drug regulation for online sales, in fact, mainly considering security issues. Because the production chain of drugs contains complex links, from production to use are tied to a long chain, any loop has problems, the damage is huge and it is difficult to determine the responsibility. Therefore, Liu Huadong, a researcher at the China National Institute of Standardization, once said that from the current problems of counterfeit drugs and vaccines, it can be seen that the entire chain traceability system of pharmaceutical products has reached the point where it has to be built and has to be managed.
Recently, Ziyun Co., Ltd. announced that it has signed the "Xinhuanet Medicare Drug Assurance Verification Data Platform Drug Traceability Code Data Matching Agreement" with Xinhuanet.
Xinhuanet is a joint stock limited company established under the laws of China and is a comprehensive news information service portal hosted by the Xinhua News Agency. The announcement shows that the two parties reached a consensus on the platform-related issues of the drug traceability code data query under the “medical insurance drug†verification scenario. In the future, we will work together to provide public inquiry services for medical insurance management agencies to request inquiries and check drug information through drug traceability codes.
This means that the trace data of Ziyun medicine can be used as the basis for data verification by medical insurance institutions. The two parties agreed to support each other in the "medical insurance drug" forensic traceability market service, which is conducive to providing comprehensive, convenient, efficient and efficient services for corporate customers such as pharmaceutical companies and merchants.
Ziyun was established in Henan in October 2002. In May 2017, Ziyun was officially listed in the National SME Share Transfer System. Ziyun Co., Ltd. builds an integrated system from the four directions of consulting, software, integration, and IT service management, and is committed to the high-tech services of IT frontier development.
In terms of drug traceability data, Ziyun Co., Ltd. can use the blockchain technology to realize the inability to tamper with various data in the production and distribution of food and medicine, and ensure the trustworthiness of food and drug traceability data; all parties through the blockchain can obtain a transparent and reliable The unified information platform can view the status in real time, reduce logistics costs, and trace the entire process of production and delivery of items, thereby improving the efficiency of supply chain management.
Ziyun has established a series of “leading chain + food and drug traceability†and “Internet + smart logistics†platforms in the direction of the Internet of Things, mobile Internet, cloud computing, big data and blockchain, and has developed a series of leading industries. Products based on SaaS and BaaS models. Among them, the traceability anti-counterfeiting platform based on blockchain technology provides food and drug companies, national regulatory authorities and ordinary consumers with BaaS services based on one-two-coded, full-process traceability, supervision and authenticity.
Based on such a strategy, Ziyun has also made relevant actions in recent days. Yesterday, Ziyun also signed a "Strategic Cooperation Agreement" on "Drug Sources and Anti-Counterfeiting Integrated Service Business" with Tencent. At the same time, Ziyun said that it will build a nationwide pharmaceutical industry blockchain alliance chain based on the underlying technology of the Tencent Blockchain-based BaaS open platform, and build on the basis of the underlying technology provided by the Tencent blockchain. "National pharmaceutical industry traceability anti-counterfeiting service platform" and related applications, for the people to provide the traditional WeChat small program used to identify drugs in the daily purchase of drugs - "Ziyun micro-drilling", to create a "drug traceability anti-counterfeiting integration Cloud service platform to solve drug safety problems to the greatest extent.
The signing of this agreement between Ziyun and Tencent actually marks the beginning of the cooperation between Ziyun and Tencent to enter the third-party service market for drug traceability. Based on the “National Pharmaceutical Industry Blockchain Allianceâ€, the alliance chain aims to create a “medical traceability and anti-counterfeiting integrated cloud service platform†and a “pharmaceutical logistics and mutual trust service platform†based on blockchain, which is the first in the world to realize pharmaceutical products. The minimum packaging traces back to the logistics trajectory and temperature and humidity of the drug, meets the rigid demand of the pharmaceutical company for the third-party traceability service of the drug, and meets the policy requirements of the State Food and Drug Administration for drug traceability to achieve “one thing, one yard, and the same codeâ€.
The signing of the agreement will lay a foundation for the two parties to join hands in the drug traceability third-party service market, and will also have a significant positive impact on Ziyun's development of drug traceability third-party service market. However, such a layout also created a less good-looking data for Ziyun's earnings report.
In the 2018 semi-annual report of Ziyun Co., the operating income of Ziyun Co., Ltd. during the reporting period was 2,636,300 yuan, a decrease of 4.66% compared with the same period of last year; its operating cost was 2,352,200 yuan, compared with last year. During the same period, it increased by 207.53%; the loss attributable to the parent company was 4,871,700 yuan, an increase of 101.83% over the same period of last year. The main reason for this is the increased investment in R&D and the increase in the operating costs of smart logistics. In fact, Ziyun has continued to transform its cloud computing and blockchain technology applications following the transformation of the previous reporting period. To trace software development and technical services in the fields of anti-counterfeiting and health management.
In fact, in order to cope with the risks brought about by business transformation, Ziyun shares should accelerate the pace of R&D, experiment and marketing while increasing R&D and marketing investment, and quickly build new core competitiveness advantages in new fields.
Hearing Aid,Hearing Assist,Hearing Aid Devices,In Ear Hearing Aids
Shenzhen Sunshine Technology Co.,Ltd , https://www.yatwinsz.com